USO 24164
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)(HQP1351CG301)
Disease Types: Lymphoma & Hematologic
Eligibility Requirements:
Age ≥ 18 years old.
Diagnosis of CML-CP
Part A: Previously treated with at least two approved TKIs Part B: T315I mutation at screening.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
Written informed consent obtained prior to any screening procedures.
Patients with adequate organ functions
For more information on this trial CLICK HERE .
Available at: